ReviewInternational journal of nanomedicine2026
Bioinspired Natural Product Nanoplatforms for Precision Cancer Theranostics from Nature to Nanomedicine.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the leading health problems in the world because of tumor heterogeneity, resistance to therapy, and the fact that traditional interventions are relatively non-specific. Plant, marine, and microbial natural products exhibit varied anticancer properties, including regulation of apoptosis, oxidative stress, and multiple signaling pathways. Nevertheless, despite excellent mechanistic data, their clinical application remains constrained by poor solubility, low bioavailability, and instability, as well as by limited targeted delivery and biomarker-directed applications. In response to these issues, bioinspired nanoplatforms have emerged as a promising approach to improve the delivery and therapeutic efficacy of natural products. These systems involve biomimetic carrier systems, lipid-based and polymer-based nanoparticles, and stimuli-based nanomaterials, which can efficiently target the tumor, deliver the drugs in a controlled way, and improve pharmacokinetics. Moreover, they facilitate the combination of diagnostic imaging and therapy, which are the pillars of precision cancer theranostics. The present review introduces a comprehensive model that links natural product pharmacology, nanoplatform engineering, and interactions with the tumor microenvironment. It shows the importance of nano-bio interactions in drug uptake, distribution, and therapeutic response. Simultaneously, it critically addresses some of the most important translational challenges, including tumor heterogeneity, variability in delivery efficiency, lack of clinical validation, scaling issues, and regulatory complexity. Altogether, this review offers a balanced and integrated outlook, stating that biomarker-based approaches, standard design, and clinical relevance validation should be considered to develop natural product-based nanomedicine into an effective precision cancer theranostic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.